Skip to main content

Advertisement

Table 2 Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR uncorrected

From: Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

Year Drug/site N PD3 Excluded/lost LCF LPF ACPR Kaplan–Meier
n (%) n (%) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
2011 ASAQ
 Ujiji 73 0 8 (11.0) 13.8 (6.5–24.7) 10.8 (4.4–20.9) 75.4 (63.1–85.2) 76.1 (64.0–84.6)
 Kibaha 29 0 4 (13.8) 0 (0.0–13.7) 0 (0.0–13.7) 100 (86.3–100) 100
AL
 Muheza 32 2 (6.3) 2 (6.3) 0 (0.0–11.6) 3.3 (0.1–17.2) 96.7 (82.8–99.9) 96.9 (79.8–99.6)
2012 AL
 Chamwino 26 0 3 (11.5) 0 (0.0–14.8) 4.3 (0.1–21.9) 95.7 (78.1–99.9) 95.7 (72.9–99.4)
 Kyela 44 0 8 (18.2) 5.6 (0.7–18.7) 16.7 (6.4–32.8) 77.8 (60.8–89.9) 78.9 (62.3–88.9)
 Nagaga 62 0 23 (37.1) 0 (0.0–9.0) 0 (0.0–9.0) 100 (91.0–100) 100
2015 AL
 Kyela 80 0 16 (20.0) 4.7 (1.0–13.1) 1.6 (0.0–8.4) 93.8 (84.8–98.3) 94.1 (85.0–97.8)
DHA-PQ
 Rufiji 82 0 10 (12.2) 1.4 (0.0–7.5) 0 (0.0–5.0) 98.6 (92.5–100) 98.6 (90.8–99.8)
  1. PD3 positive on day 3, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate + amodiaquine, AL artemether + lumefantrine, DHAPQ dihydroartemisinin + piperaquine